Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Lyra Therapeutics Inc (LYRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Lyra's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.230 +0.007    +4.49%
11/10 - Closed. Currency in USD ( Disclaimer )
After Hours
0.224
-0.006
-2.609%
1:36:47 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 437,555
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.223 - 0.235
Lyra 0.230 +0.007 +4.49%

Lyra Therapeutics Inc Company Profile

 
Get an in-depth profile of Lyra Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

88

Equity Type

ORD

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Contact Information

Address 480 Arsenal Way
Watertown, 02472
United States
Phone 617 393 4600
Fax -

Top Executives

Name Age Since Title
W. Bradford Smith 66 2019 Independent Director
Gary M. Ansel - - Member of Medical Advisory Board
Martin Schillinger - - Member of Medical Advisory Board
I. Baumgartner - - Member of Medical Advisory Board
Robert S. Langer 73 2006 Member of Scientific Advisory Board
George M. Whitesides 83 2006 Member of Scientific Advisory Board
Michael D. Dake - - Member of Medical Advisory Board
William A. Gray - - Member of Medical Advisory Board
James Morley Anderson 81 - Member of Scientific Advisory Board
Mahmood K. Razavi - - Member of Medical Advisory Board
James R. Tobin 77 2022 Lead Independent Director
Maria Palasis 58 2015 CEO, President & Director
Harlan W. Waksal 70 2022 Executive Chairman
C. Ann Merrifield 72 2019 Independent Director
Robert S. Schwartz - - Member of Scientific Advisory Board
Nancy L. Snyderman 71 2020 Independent Director
Michael Seth Altman 42 2018 Independent Director
Konstantin Poukalov 40 2020 Independent Director
Stephen L. Hilbert - - Member of Scientific Advisory Board
Renu Virmani - - Member of Scientific Advisory Board
Mark Saltzman - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LYRA Comments

Write your thoughts about Lyra Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email